09 May 2022 | Features
Empowered By Innovation
Founders- Dr Bijayananda Panigrahi and Soumya Surajita
Total team strength- 8
Total funds raised- Rs 70 lakh (approx)
Investors-DBT (BIRAC-BIG), Startup Odisha
Revenue generated since inception- NA
"In the Biotech industry, validation of any product especially protease inhibitor needs a huge time, as well as target customer segment is very specific and distributed around the globe. Therefore, finding the target customer, and channelize the product network throughout the world is a major challenge associated with this type of product.
According to a market watch analysis, the protease inhibitor market will be big, with sales expected to reach $4 billion by 2028. Because it has several applications in biotechnology, medicine, microbiology, agriculture, pharmaceuticals, cosmetics, food additives, and the protein purification sector, to name a few. It could be utilized as a reagent, as well as pharmaceutical-grade compounds. We are tremendously driven to acquire a significant market in India and the subcontinent because we are the first protease inhibitor firm in India. It is one of the measures aimed at reducing India's reliance on protease inhibitor imports and achieving self-reliant India in the protease inhibitor market."
- Dr Bijayananda Panigrahi, Founder & Chief Executive Officer, Biopioneer